Abstract Details

Title Healthcare Utilization of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Patients

Topic Autoimmune Neurology

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-027

Objective To quantify and characterize the healthcare utilization of patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in our academic neuroimmunology clinic.

Background Healthcare utilization of various demyelinating diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has been documented but little research exists on the healthcare utilization of MOGAD. Further clarifying various aspects of how the healthcare system is utilized by MOGAD patients could be used to establish guidelines and treatment decisions.

Design/Methods A retrospective analysis of patients within our clinic’s database was performed. Data were collected on patients diagnosed with MOGAD from 2015 to present.

Results Eleven patients were identified with an average age of 43 (range 24-72), 5 were female (45%). Self-identified racial distribution was white/Caucasian (5), black/African American (3), Asian (1) and two declined or were unable to respond. Average length of disease was 46 months (range 1-204 months). Average frequency of clinic visits was a visit every 3.7 months (range 1-8.7). Average frequency of MRIs was one every 10.9 months (range 1-11). Majority (8 of 11, 72%) were on B-cell depleting therapy; others were on mycophenolate mofetil (2, 18%) and IVIg (1, 9%). 5/11 (45%) had a hospitalization after their initial diagnosis. Average number of symptomatic medications was 1 (range 0-4) and average number of referrals was 0.7 (range 0-2). Majority of the medications were for psychiatric comorbidities while majority of referrals were to neuro-ophthalmology.

Conclusions MOGAD patients utilize multiple aspects of the healthcare system for maintenance of their disease or exacerbations, similarly to MS and NMOSD. However, when compared to MS, MOGAD patients had higher hospitalization rates, even with the majority on maintenance use of B-cell depleting therapy, indicating the need for further studies on optimal treatments for MOGAD patients.

Authors/Disclosures
Kelsey Stefan, MD (University of South Florida) PRESENTER	Ms. Stefan has nothing to disclose.
Ribal N. Haddad, MD (Carle Health)	Dr. Haddad has nothing to disclose.
Derrick Robertson, MD	Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Greenwich Biosciences. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi Genzyme. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mallinckrodt. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Robertson has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Robertson has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Genentech. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for PRIME CME. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Janssen. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Horizon. Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for McVeigh. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Mccumber. Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Goodis. The institution of Dr. Robertson has received research support from Biogen. The institution of Dr. Robertson has received research support from EMD Serono. The institution of Dr. Robertson has received research support from Jansenn. The institution of Dr. Robertson has received research support from Genentech. The institution of Dr. Robertson has received research support from Patient-Centered Outcomes Research Institute. The institution of Dr. Robertson has received research support from Novartis. The institution of Dr. Robertson has received research support from Sanofi Genzyme. The institution of Dr. Robertson has received research support from TG Therapeutics. The institution of Dr. Robertson has received research support from Prime. The institution of Dr. Robertson has received research support from Greenwich Biosciences. The institution of Dr. Robertson has received research support from Atara Biotherapeutics. The institution of Dr. Robertson has received research support from CorEvitas. The institution of Dr. Robertson has received research support from Anokion. The institution of Dr. Robertson has received research support from UCB Biosciences. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Consortium of Multiple Sclerosis Centers. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Multiple Sclerosis Association of America.

��ɫ��

��ɫ��